Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma (Nasdaq: RPRX) will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Investors can obtain conference call details and view the live webcast via the company's Investors page, and a replay will be archived on the site for at least 30 days.
Royalty Pharma (Nasdaq: RPRX) provided a business update and will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Key highlights: the announced royalty funding market reached a record $10 billion in 2025; Royalty Pharma announced $4.7 billion of transactions in 2025 (capital deployment of $2.6 billion), representing ~40% market share. The company expects to meet 2025 Portfolio Receipts guidance of $3,200–$3,250 million (14%–16% growth) and reported trailing twelve‑month ROIC 15.7% and ROIE 22.9%. Multiple 2026 milestones are anticipated, including pivotal readouts for daraxonrasib, litifilimab and pelacarsen, and several potential approvals; late‑stage pipeline peak sales potential exceeds $43 billion, which could translate to >$2.1 billion annually in new royalties.
Royalty Pharma (Nasdaq: RPRX) agreed to provide up to $500 million to accelerate Teva's anti‑IL‑15 antibody, TEV‑'408, including $75 million of R&D co‑funding to support a Phase 2b vitiligo study targeted to start in 2026 and a Royalty Pharma option to provide an additional $425 million to co‑fund a Phase 3 program. TEV‑'408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, and Teva expects to share trial results during 2026.
If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV‑'408.
Royalty Pharma (Nasdaq: RPRX) announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase versus the prior quarter. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.
Royalty Pharma (Nasdaq: RPRX) acquired the remaining portion of PTC Therapeutics’ royalty on Roche’s Evrysdi for $240 million upfront plus up to $60 million in sales‑based milestones. Following the deal, Royalty Pharma will own 100% of a tiered 8%–16% royalty on worldwide net sales of Evrysdi.
Evrysdi is an oral SMN2 splicing modifier for spinal muscular atrophy, FDA approved in 2020 and used by >21,000 patients. Evrysdi reported CHF 1.6 billion (~$1.9B) sales in 2024, +18% year‑over‑year at constant FX, and analyst consensus projects CHF 2.3 billion (~$2.9B) by 2030. The increased royalty structure applies starting Q1 2026, based on Q4 2025 product sales.
Royalty Pharma (Nasdaq: RPRX) acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from a third party for up to $315 million.
Both are next-generation TKIs for ALK and ROS1 mutation-positive NSCLC. Neladalkib reported positive pivotal results in November 2025 and is in a Phase 3 study in TKI-naïve patients. Zidesamtinib is under U.S. FDA review with an action date of September 18, 2026 and is in Phase 1/2 for TKI-naïve patients.
Royalty Pharma acquired a low-single-digit royalty on worldwide net sales, with expected royalty duration through approximately 2041–2042. Existing analyst consensus projects peak sales of about $3.5B for neladalkib and $1.9B for zidesamtinib by 2035.
Royalty Pharma (Nasdaq: RPRX) agreed to provide $275 million in synthetic royalty funding to Denali Therapeutics (Nasdaq: DNLI) tied to future net sales of tividenofusp alfa for MPS II (Hunter syndrome).
Royalty Pharma will pay $200 million at closing and an additional $75 million upon EMA approval by Dec 31, 2029. In return, Royalty Pharma receives a 9.25% royalty on worldwide net sales, capped at a 3.0x multiple (or 2.5x if reached by Q1 2039). The transaction requires U.S. FDA accelerated approval (PDUFA date Apr 5, 2026).
Royalty Pharma (Nasdaq: RPRX) will present at two investor conferences in early December 2025: Citi 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ET and Evercore 8th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET.
The company said webcasts of both presentations will be available on its Events page and archived for a minimum of 30 days, allowing investors to view the presentations after the live sessions.
Royalty Pharma (Nasdaq: RPRX) reported Q3 2025 Portfolio Receipts of $814M, up 11% year-over-year, and Royalty Receipts of $811M, up 11%. Net cash provided by operating activities was $703M. The company raised full‑year 2025 Portfolio Receipts guidance to $3.20B–$3.25B (growth ~14%–16%).
Recent capital deployment accelerated: announced transactions up to $3.8B year-to-date and acquired royalties including Imdelltra (up to $950M), obexelimab (up to $300M) and Amvuttra ($310M). Cash was $939M and total debt principal was $9.2B as of September 30, 2025. Share repurchases totaled $1.2B in the first nine months of 2025.
Royalty Pharma (Nasdaq: RPRX) acquired a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences for $310 million. Royalty Pharma purchased Blackstone’s 1% royalty on worldwide net sales covering AMVUTTRA sales beginning October 1, 2025, with the royalty extending through March 2035. AMVUTTRA is an FDA-approved RNAi therapeutic for ATTR amyloidosis; sales were approximately $1 billion in 2024 (+74% year-over-year) and analyst consensus projects sales to exceed $6 billion by 2028. The company said the deal aligns with its return targets across scenarios that include potential competition from Alnylam’s follow-on product nucresiran. Advisors on the transaction were disclosed for both parties.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
